Why Vogenx, Inc.’s (VOGX) Stock Is Down 9.27%
As of Thursday, October 22, Vogenx, Inc.’s VOGX share price has dipped by 9.27%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Commentary & Analysis
Why Vogenx, Inc.’s (VOGX) Stock Is Down 10.25%
As of Thursday, October 22, Vogenx, Inc.’s VOGX share price has dipped by 10.25%, which has investors questioning if this is right time to buy.Omar Beirat
Why Vogenx, Inc.’s (VOGX) Stock Is Up 10.61%
As of Wednesday, October 21, Vogenx, Inc.’s VOGX share price has surged by 10.61%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Vogenx, Inc.’s (VOGX) Stock Is Up 7.41%
As of Tuesday, October 20, Vogenx, Inc.’s VOGX share price has surged by 7.41%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Vogenx, Inc.’s (VOGX) Stock Is Up 7.85%
As of Monday, October 19, Vogenx, Inc.’s VOGX share price has surged by 7.85%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | VOGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $283.4 | $500.9 | 32% |
|
| Shares Out (Mil) | 5.5 | 42.7 | 15% |
|
| Institutional Ownership | 31.2% | 81.3% | 13% |
|
| Float (Mil) | 9.8 | 45.6 | 19% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 96 | 303 | 36% |
|
| Price Change (52-week) |
na | 56.3% | na |
|
| Growth | VOGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VOGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($2) | ($11) | 37% |
|
| EPS (TTM) | ($0.303) | ($0.700) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($1) | ($7) | 31% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $484 | $493 | 34% |
|
| Valuation | VOGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.09 | na |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | VOGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (234.8%) | (22.2%) | 2% |
|
| ROE | 185.9% | (21.0%) | 98% |
|
| Liabilities to Assets | 226.3% | 32.3% | 99% |
|
| F-Score | 1 | 3 | na |
|
Vogenx, Inc. did not pass any screens on 10/22/2026.
